Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 308

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 308
---
 adverse judgment granting permanent injunctive relief could indefinitely enjoin consummation of the Merger. • Fees and expenses.The fees and expenses associated with completing the Merger. • Potential impacts of COVID -19 .Uncertainties regarding the potential impacts of the COVID -19virus and related economic disruptions on Profusa’s operations. • Other risk factors.Various other risk factors associated with the respective businesses of NorthView and Profusa as described in the section entitled “ Risk Factors” appearing elsewhere in this proxy statement/prospectus. The NorthView Board concluded that the potential benefits expected for NorthView and its stockholders as a result of the Merger outweighed the any potentially negative factors related to the Merger. Accordingly, the NorthView Board unanimously determined that the Merger Agreement, and the transactions contemplated thereby, including the Merger, were advisable, fair to and in the best interests of NorthView and its stockholders. Profusa Reasons for the Merger In the course of reaching its decision to approve the merger, the Profusa board of directors held numerous meetings, consulted with Profusa’s senior management, its financial advisors and legal counsel, and considered a wide variety of factors including, among others, the following material factors (which factors are not necessarily presented in any order of relative importance): •the merger will provide Profusa’s current stockholders with greater liquidity by owning publicly -tradedstock, and expanding both the access to capital for Profusa and the range of investors potentially available as a public company, compared to the investors Profusa could otherwise gain access to if it continued to operate as a privately -heldcompany; •the potential benefits from increased public market awareness of Profusa and its products; •the historical and current information concerning Profusa’s business, including its financial performance and condition, operations, management and pre -clinicaland clinical data; •the competitive nature of the industry in which Profusa operates; 155 •the Profusa board of directors’ fiduciary duties to Profusa’s stockholders; •the board’s belief that this transaction provides a viable public listing strategy, and addresses the risk of the lack of an available market for an initial public offering at a later date; •the expected cash resources of the combined organization (including the ability to support the combined company’s current and planned operations); •the terms and conditions of the Merger Agreement; •certain shares of New Profusa Common Stock issued to Profusa’s stockholders will be registered on a Form S -4registration statement and will become freely trad